The Experimental Irradiator Core, which has been in existence since 1986, maintains and operates sources of ionizing radiation for use by Cancer Center members in their experimental studies. Services performed by the resource staff include training in the operation of the sources, advice to users on the design of experiments using radiation, scheduling use of the sources, operating the sources when necessary, dosimetry for new experimental setups, and maintenance and repair of the resources. When not in use by members, these facilities are also available to non-members on an increased-fee basis. The primary resources of the facility are six Cs-137 irradiators. Three Nordion Gammacell 40 irradiators are primarily used for whole body irradiation of rodents or irradiation of attached cultured cells at a constant dose rate: The Shepherd Mark I irradiator is used primarily to deliver radiation to animal tumors or other partialbody irradiations at dose rates comparable to those used in external beam radiotherapy. However, this irradiator can deliver radiation at a broad range of dose rates for a variety of purposes, such as irradiation of cell suspensions or irradiation to high doses to sterilize implant material. The Gammacell 1000 irradiator is used to irradiate suspension cultures at a constant dose rate. The low-dose-rate irradiator, built in-house with a Shepherd 81 source, is used primarily to irradiate cell cultures at dose rates comparable to those used in tumor therapy with radioactive implants, but can deliver radiation at any rate below 2 Gy/hr and has also been used in studies of carcinogenesis from prolonged exposure to low-dose-rate radiation. It is anticipated that in 2008 an in-house-built image-guided small animal radiation research platform (SARRP) will be available to the Core facility. The SARRP is designed to produce the same degree of dose delivery precision in animal models as is currently achievable in human patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-48
Application #
8117665
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-05-01
Budget End
2011-04-30
Support Year
48
Fiscal Year
2010
Total Cost
$27,630
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Popovic, Aleksandra; Jaffee, Elizabeth M; Zaidi, Neeha (2018) Emerging strategies for combination checkpoint modulators in cancer immunotherapy. J Clin Invest 128:3209-3218
Peprah, Sally; Curreiro, Frank C; Hayes, Jennifer H et al. (2018) A spatiotemporal analysis of invasive cervical cancer incidence in the state of Maryland between 2003 and 2012. Cancer Causes Control 29:445-453
Springer, Simeon U; Chen, Chung-Hsin; Rodriguez Pena, Maria Del Carmen et al. (2018) Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. Elife 7:
Handy, Catherine E; Antonarakis, Emmanuel S (2018) Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. Future Oncol 14:907-917
Dean, Lorraine T; Schmitz, Kathryn H; Frick, Kevin D et al. (2018) Consumer credit as a novel marker for economic burden and health after cancer in a diverse population of breast cancer survivors in the USA. J Cancer Surviv 12:306-315
Zhang, Jiajia; Wolfgang, Christopher L; Zheng, Lei (2018) Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer. Cancers (Basel) 10:
Leadem, Benjamin R; Kagiampakis, Ioannis; Wilson, Catherine et al. (2018) A KDM5 Inhibitor Increases Global H3K4 Trimethylation Occupancy and Enhances the Biological Efficacy of 5-Aza-2'-Deoxycytidine. Cancer Res 78:1127-1139
Danilova, Ludmila; Anagnostou, Valsamo; Caushi, Justina X et al. (2018) The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity. Cancer Immunol Res 6:888-899
Jackson, Sadhana; Weingart, Jon; Nduom, Edjah K et al. (2018) The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS 15:2
Dejea, Christine M; Fathi, Payam; Craig, John M et al. (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592-597

Showing the most recent 10 out of 2393 publications